PURPOSE: Despite the fact that extra virgin olive oil (EVOO) is widely used in obese individuals to treat cardiovascular diseases, the role of EVOO on weight/fat reduction remains unclear. We investigated the effects of energy-restricted diet containing EVOO on body composition and metabolic disruptions related to obesity. METHODS: This is a randomized, double-blinded, placebo-controlled clinical trial in which 41 adult women with excess body fat (mean ± SD 27.0 ± 0.9 year old, 46.8 ± 0.6% of total body fat) received daily high-fat breakfasts containing 25 mL of soybean oil (control group, n = 20) or EVOO (EVOO group, n = 21) during nine consecutive weeks. Breakfasts were part of an energy-restricted normal-fat diets (-2090 kJ, ~32%E from fat). Anthropometric and dual-energy X-ray absorptiometry were assessed, and fasting blood was collected on the first and last day of the experiment. RESULTS:Fat loss was ~80% higher on EVOO compared to the control group (mean ± SE: -2.4 ± 0.3 kg vs. -1.3 ± 0.4 kg, P = 0.037). EVOO also reduced diastolic blood pressure when compared to control (-5.1 ± 1.6 mmHg vs. +0.3 ± 1.2 mmHg, P = 0.011). Within-group differences (P < 0.050) were observed for HDL-c (-2.9 ± 1.2 mmol/L) and IL-10 (+0.9 ± 0.1 pg/mL) in control group, and for serum creatinine (+0.04 ± 0.01 µmol/L) and alkaline phosphatase (-3.3 ± 1.8 IU/L) in the EVOO group. There was also a trend for IL-1β EVOO reduction (-0.3 ± 0.1 pg/mL, P = 0.060). CONCLUSION:EVOO consumption reduced body fat and improved blood pressure. Our results indicate that EVOO should be included into energy-restricted programs for obesity treatment.
RCT Entities:
PURPOSE: Despite the fact that extra virgin olive oil (EVOO) is widely used in obese individuals to treat cardiovascular diseases, the role of EVOO on weight/fat reduction remains unclear. We investigated the effects of energy-restricted diet containing EVOO on body composition and metabolic disruptions related to obesity. METHODS: This is a randomized, double-blinded, placebo-controlled clinical trial in which 41 adult women with excess body fat (mean ± SD 27.0 ± 0.9 year old, 46.8 ± 0.6% of total body fat) received daily high-fat breakfasts containing 25 mL of soybean oil (control group, n = 20) or EVOO (EVOO group, n = 21) during nine consecutive weeks. Breakfasts were part of an energy-restricted normal-fat diets (-2090 kJ, ~32%E from fat). Anthropometric and dual-energy X-ray absorptiometry were assessed, and fasting blood was collected on the first and last day of the experiment. RESULTS: Fat loss was ~80% higher on EVOO compared to the control group (mean ± SE: -2.4 ± 0.3 kg vs. -1.3 ± 0.4 kg, P = 0.037). EVOO also reduced diastolic blood pressure when compared to control (-5.1 ± 1.6 mmHg vs. +0.3 ± 1.2 mmHg, P = 0.011). Within-group differences (P < 0.050) were observed for HDL-c (-2.9 ± 1.2 mmol/L) and IL-10 (+0.9 ± 0.1 pg/mL) in control group, and for serum creatinine (+0.04 ± 0.01 µmol/L) and alkaline phosphatase (-3.3 ± 1.8 IU/L) in the EVOO group. There was also a trend for IL-1β EVOO reduction (-0.3 ± 0.1 pg/mL, P = 0.060). CONCLUSION:EVOO consumption reduced body fat and improved blood pressure. Our results indicate that EVOO should be included into energy-restricted programs for obesity treatment.
Entities:
Keywords:
Adiposity; Blood pressure; Body fat; Extra virgin olive oil; Monounsaturated fatty acid; Soybean oil
Authors: Ramon Estruch; Miguel Angel Martínez-González; Dolores Corella; Jordi Salas-Salvadó; Valentina Ruiz-Gutiérrez; María Isabel Covas; Miguel Fiol; Enrique Gómez-Gracia; Mari Carmen López-Sabater; Ernest Vinyoles; Fernando Arós; Manuel Conde; Carlos Lahoz; José Lapetra; Guillermo Sáez; Emilio Ros Journal: Ann Intern Med Date: 2006-07-04 Impact factor: 25.391
Authors: J López-Miranda; F Pérez-Jiménez; E Ros; R De Caterina; L Badimón; M I Covas; E Escrich; J M Ordovás; F Soriguer; R Abiá; C Alarcón de la Lastra; M Battino; D Corella; J Chamorro-Quirós; J Delgado-Lista; D Giugliano; K Esposito; R Estruch; J M Fernandez-Real; J J Gaforio; C La Vecchia; D Lairon; F López-Segura; P Mata; J A Menéndez; F J Muriana; J Osada; D B Panagiotakos; J A Paniagua; P Pérez-Martinez; J Perona; M A Peinado; M Pineda-Priego; H E Poulsen; J L Quiles; M C Ramírez-Tortosa; J Ruano; L Serra-Majem; R Solá; M Solanas; V Solfrizzi; R de la Torre-Fornell; A Trichopoulou; M Uceda; J M Villalba-Montoro; J R Villar-Ortiz; F Visioli; N Yiannakouris Journal: Nutr Metab Cardiovasc Dis Date: 2010-03-19 Impact factor: 4.222
Authors: James M Ntambi; Makoto Miyazaki; Jonathan P Stoehr; Hong Lan; Christina M Kendziorski; Brian S Yandell; Yang Song; Paul Cohen; Jeffrey M Friedman; Alan D Attie Journal: Proc Natl Acad Sci U S A Date: 2002-08-12 Impact factor: 11.205
Authors: Adela Hruby; JoAnn E Manson; Lu Qi; Vasanti S Malik; Eric B Rimm; Qi Sun; Walter C Willett; Frank B Hu Journal: Am J Public Health Date: 2016-07-26 Impact factor: 9.308
Authors: Teresa T Fung; Kathryn M Rexrode; Christos S Mantzoros; JoAnn E Manson; Walter C Willett; Frank B Hu Journal: Circulation Date: 2009-02-16 Impact factor: 29.690
Authors: S Terés; G Barceló-Coblijn; M Benet; R Alvarez; R Bressani; J E Halver; P V Escribá Journal: Proc Natl Acad Sci U S A Date: 2008-09-04 Impact factor: 11.205
Authors: Marta Farràs; Laura Martinez-Gili; Kevin Portune; Sara Arranz; Gary Frost; Mireia Tondo; Francisco Blanco-Vaca Journal: Nutrients Date: 2020-07-23 Impact factor: 5.717
Authors: Erika Aparecida Silveira; Jacqueline Danésio de Souza; Ana Paula Dos Santos Rodrigues; Ricardo M Lima; Camila Kellen de Souza Cardoso; Cesar de Oliveira Journal: Nutrients Date: 2020-05-21 Impact factor: 5.717